RECRUITING

Sleep and Metabolism

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to uncover sleep and circadian mechanisms contributing to adverse metabolic health. The protocol is a 21 day (7 outpatient days, 14 inpatient days) mechanistic randomized-crossover study designed to identify the impact of chronic sleep restriction and circadian timing, independently and in combination on energy metabolism and identify the independent and combined effects on glucose tolerance.

Official Title

Uncovering Sleep and Circadian Mechanisms Contributing to Adverse Metabolic Health

Quick Facts

Study Start:2023-12-01
Study Completion:2027-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05775627

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Between 18 and 40 years of age
  2. * Drug free
  3. * Established disease-free status
  1. 1. Dietary restrictions
  2. * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)
  3. 2. Body Composition
  4. 3. Psychiatric/psychological suitability
  5. * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician
  6. * A history of severe psychiatric illnesses
  7. * Alcoholism
  8. * Drug dependency
  9. * Major depression
  10. * Manic depressive illness
  11. * Schizophrenic disorders
  12. * Panic disorder
  13. * Generalized anxiety disorder
  14. * Post-traumatic stress disorder
  15. * Agoraphobia
  16. * Claustrophobia
  17. * Paranoid personality disorder
  18. * Schizoid personality disorder
  19. * Schizotypal personality disorder
  20. * Borderline personality disorder
  21. * Antisocial personality disorder.
  22. * History of using antidepressant medication
  23. * History of using neuroleptic medication
  24. * History of using tranquilizers
  25. 4. Drug/alcohol use
  26. * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking
  27. 5. Medication/drug use
  28. 6. Prior shift work
  29. * Working irregular day and night hours
  30. * Regular night work
  31. * Rotating shift work f
  32. * Not have traveled more than 1 time zone during 3 months prior to the study
  33. 7. Chronobiologic and sleep disorders
  34. * Hypernychthemeral sleep/wake cycle
  35. * Delayed sleep phase syndrome (wake time \> 2 hours later than desired or habitually after 10:00 AM)
  36. * Advanced sleep phase syndrome (wake time \> 2 h earlier than desired or habitually before 5:00 AM)
  37. * Narcolepsy
  38. * Sleep apnea (apnea index \>15)
  39. * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \< 80%)
  40. * Hypersomnia
  41. * Periodic Limb Movement (PLMS) (PLMS index \>15)
  42. * Nocturnal Paroxysmal Dystonia
  43. * REM-sleep behavior disorder
  44. * Nocturnal Enuresis; (self-report and first night in the laboratory)
  45. * Obstructive sleep apnea (apnea/hypopnea index \>5/h as determined by at-home monitoring)
  46. * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire)
  47. 8. Diseases of the Cardiovascular System
  48. * Hypertension (systolic blood pressure \> 140 or diastolic blood pressure \> 90)
  49. * Heart failure
  50. * Cardiomyopathy
  51. * Cor pulmonale
  52. * Ischemic heart disease
  53. * Valvular heart disease
  54. * History of heart transplantation
  55. * Cardiac tumors
  56. * Pericardial disease
  57. 9. Metabolic Syndrome
  58. * HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
  59. * Systolic blood pressure \>135 mmHg or diastolic blood pressure \>85 mmHg
  60. * Fasting blood glucose ≥ 100 mg/dL
  61. * Triglycerides ≥ 150 mg/dL
  62. 10. Pre-Diabetes/Diabetes
  63. 11. Hypertension
  64. 12. Disorders of the Respiratory System
  65. * Asthma
  66. * Cystic fibroses
  67. * Chronic bronchitis
  68. * Emphysema
  69. * Airway obstruction
  70. * Interstitial lung diseases
  71. * Pulmonary hypertension
  72. * Lung neoplasms
  73. * ARDS
  74. 13. Disorders of the Kidney and Urinary Tract
  75. * Acute or chronic renal failure
  76. * History of renal transplantation
  77. * Tubulointerstitial diseases of the kidney
  78. * Urinary tract obstruction
  79. * Tumors of the urinary tract
  80. 14. Infectious Diseases
  81. * Infective endocarditis
  82. * HIV infection
  83. * Sexually transmitted diseases \[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\],
  84. * Urinary tract infection
  85. * Osteomyelitis
  86. * Brucellosis
  87. * Toxoplasmosis,
  88. * Tuberculosis
  89. * Leptospirosis
  90. * Lyme disease
  91. * Mononucleosis
  92. * Hepatitis
  93. * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis
  94. 15. Disorders of the Gastrointestinal System
  95. * Esophagitis
  96. * Peptic ulcer and gastritis
  97. * Neoplasms of the esophagus, stomach or bowel
  98. * Disorders of absorption
  99. * Inflammatory bowel disease
  100. * Diseases of the small and large intestine
  101. * Acute appendicitis
  102. * Cirrhosis or neoplasms of the liver
  103. * History of liver transplantation
  104. * Diseases of the gallbladder and bile ducts
  105. * Pancreatic disease
  106. 16. Disorders of the Immune System, Connective Tissue and Joints
  107. * AIDS
  108. * Systemic lupus erythematosus
  109. * Rheumatoid arthritis
  110. * Scleroderma
  111. * Ankylosing spondylitis
  112. * Vasculitis
  113. * Sarcoidosis
  114. 17. Disorders of the Hematopoietic System
  115. * Anemia
  116. * Leukemia
  117. * Myeloproliferative diseases
  118. * History of bone marrow transplantation
  119. 18. Neoplastic Diseases
  120. * Lymphoma
  121. * Carcinoma
  122. * Melanoma
  123. * Any other neoplastic diseases
  124. 19. Endocrine and Metabolic Diseases
  125. * Thyroid disease
  126. * Addison's Disease
  127. * Cushing's Syndrome
  128. * Aldosteronism
  129. * Hypoaldosteronism
  130. * Pheochromocytoma
  131. * Disorders of sexual differentiation that require hormone supplementation that may alter body weight
  132. * Disorders of neuroendocrine regulation
  133. * Diseases of the anterior pituitary and hypothalamus
  134. * Hemochromatosis porphyria
  135. * Wilson's Disease
  136. * Glycogen storage diseases
  137. * Diseases of the parathyroid gland
  138. * Metabolic bone disease
  139. * Disorders of phosphorus or magnesium metabolism
  140. * Paget's Disease
  141. 20. Neurologic Disorders
  142. * Epilepsy and disorders of consciousness
  143. * Dementia
  144. * Amnesic disorders
  145. * Neoplastic diseases of the central nervous system
  146. * Demyelinating diseases
  147. * Parkinson's Disease
  148. * Muscular dystrophy
  149. * Myasthenia gravis
  150. * Periodic paralysis
  151. * Dermatomyositis
  152. * Polymyositis
  153. * Infections of the nervous system
  154. * Stroke
  155. * History of transient ischemic attacks
  156. * Hydrocephalus
  157. * Tumors of the pituitary gland
  158. * Pinealoma
  159. * Intervertebral disc disease
  160. * Ataxia
  161. * Gilles de la Tourette Syndrome
  162. * Huntington's Disease
  163. * Tardive dyskinesia
  164. * History of recurrent migraine headaches
  165. * Neuromuscular disease.
  166. 21. Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:
  167. * Ingest experimental medication
  168. * Give blood samples

Contacts and Locations

Study Contact

Andrew McHill, PhD
CONTACT
503-494-2594
mchill@ohsu.edu

Principal Investigator

Andrew McHill, PhD
PRINCIPAL_INVESTIGATOR
Oregon Health and Science University

Study Locations (Sites)

Oregon Health & Science University
Portland, Oregon, 97239
United States

Collaborators and Investigators

Sponsor: Oregon Health and Science University

  • Andrew McHill, PhD, PRINCIPAL_INVESTIGATOR, Oregon Health and Science University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-01
Study Completion Date2027-06-30

Study Record Updates

Study Start Date2023-12-01
Study Completion Date2027-06-30

Terms related to this study

Keywords Provided by Researchers

  • sleep restriction
  • obesity
  • glucose intolerance
  • weight gain
  • circadian timing
  • ad libitum
  • food selection

Additional Relevant MeSH Terms

  • Sleep Deprivation
  • Obesity
  • Glucose Intolerance
  • Weight Gain
  • Food Selection